|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00315510 |
|
Date of registration:
|
14/04/2006 |
|
Primary sponsor: |
|
|
Public title:
|
Rosuvastatin and Ischemia Reperfusion
|
|
Scientific title:
|
Does Rosuvastatin Reduce Ischemia/Reperfusion Injury in Humans In-Vivo? A Randomized Double Blind Placebo Controlled Trial |
|
Date of first enrolment:
|
April 2006 |
|
Target sample size:
|
20 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00315510 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
Netherlands
| | | | | | | |
|
Contacts
|
|
Name:
|
Gerard A. Rongen, MD, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Dept. of Pharmacology-Toxicology; Radboud University Medical Centre |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Healthy volunteers (18-50 years of age)
Exclusion Criteria:
- Hypercholesterolemia
- Hypertension
Age minimum:
18 Years
Age maximum:
50 Years
Gender:
Male
|
|
Health Condition(s) or Problem(s) studied
|
|
Ischemia
|
|
Intervention(s)
|
|
Drug: Rosuvastatin
|
|
Primary Outcome(s)
|
|
annexin A5 targeting to ischemically exercised hand
|
|
Secondary Outcome(s)
|
|
plasma lipid levels
|
|
Secondary ID(s)
|
|
QPhT05_131005-Rosuvastatine
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|